Τίτλος:
Neutrophil-to-lymphocyte ratio and chemotherapy response score as
prognostic markers in ovarian cancer patients treated with neoadjuvant
chemotherapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Neoadjuvant chemotherapy (NACT) followed by interval
debulking surgery (IDS) is the recommended approach in patients with
advanced epithelial ovarian cancer (EOC). However, most patients
eventually relapse despite the initial high response rate to
chemotherapy. Neutrophil-to-lymphocyte ratio is a well-known biomarker
that reflects severe inflammation, critical illness, and mortality in
various diseases. Chemotherapy response score (CRS) and
neutrophil-to-lymphocyte ratio (NLR) have been identified as potential
biomarkers of platinum resistance and disease prognosis. We
retrospectively evaluated 132 patients with stage IIIc or IV
ovarian/fallopian tube/primary peritoneal cancer who had received NACT
followed by IDS from 01/01/2003 to 31/12/2018. CRS was assessed on
omental specimens collected from IDS according to ICCR guidelines.
Results: Median age was 64.57 years (SD: 9.72; range 39.2-87.1). Most
ovarian tumors were serous epithelial (90.9%; 120/132). An elevated NLR
(defined as > 3) was observed in 72% (95/132) of patients in contrast
with 28% (37/132) of patients characterized by low NLR status. Median
PFS (mPFS) and median overall survival (mOS) were 13.05 months (95% CI:
11.42-14.67)) and 34.69 months (95% CI: 23.26-46.12) respectively. In
univariate analysis, CRS3 score was significantly associated with
prolonged mPFS (CRS1/2: 12.79 months vs CRS3: 17.7 months; P = 0.008).
CRS score was not associated with mOS (P = 0.876). High NLR was not
significantly associated with mPFS (P = 0.128), however it was
significantly associated with poor mOS (P = 0.012). In multivariate
analysis, only performance of surgery maintained its statistical
significance with both PFS (P = 0.001) and OS (P = 0.008).
Conclusion: NLR could serve as a useful predictor of OS but not PFS in
ovarian cancer patients receiving NACT. In accordance with our previous
study, CRS score at omentum was found to be associated with PFS but not
OS in ovarian cancer patients treated with NACT and IDS.
Συγγραφείς:
Liontos, M.
Andrikopoulou, A.
Koutsoukos, K.
Markellos, C.
and Skafida, E.
Fiste, O.
Kaparelou, M.
Thomakos, N. and
Haidopoulos, D.
Rodolakis, A.
Dimopoulos, M. A.
Zagouri, F.
Περιοδικό:
Journal of Ovarian Research
DOI:
10.1186/s13048-021-00902-0
